Chyl-Surdacka Katarzyna M, Gerkowicz Agnieszka, Bartosińska Joanna, Kowal Małgorzata, Przepiórka-Kosińska Joanna, Surdacki Gabriel, Krasowska Dorota, Chodorowska Grażyna
Department of Dermatology, Venereology and Paediatric Dermatology, Medical University of Lublin, Lublin, Poland.
Department of Urology and Urological Oncology, John of God Regional Hospital, Lublin, Poland.
Postepy Dermatol Alergol. 2019 Oct;36(5):531-537. doi: 10.5114/ada.2019.89503. Epub 2019 Nov 12.
Recent data depict psoriasis as a systemic disease with many comorbidities, especially metabolic syndrome and cardiovascular diseases. Chemerin, an adipokine secreted by adipose tissue cells, may prove to be an important link between psoriasis and its comorbidities.
Assessment of serum concentrations of chemerin in patients with psoriasis and the healthy control group as well as evaluation of a possible correlation between adipokine concentrations and selected psoriasis severity indices and metabolic syndrome components.
One hundred and two patients with diagnosed psoriasis and 40 healthy volunteers were enrolled in the study. In all subjects, serum chemerin concentrations and selected metabolic syndrome components including lipid and glucose levels were determined. Psoriasis severity was assessed using the PASI and BSA indices.
A higher concentration of chemerin was demonstrated in the group of psoriasis patients compared to the control group ( < 0.05). A positive correlation between chemerin concentration and C-reactive protein concentration ( = 0.001), body mass index ( = 0.031) and triglyceride concentration ( = 0.043) was found. An inverse correlation with high-density lipoprotein cholesterol concentrations ( = 0.015) was also noted. Significantly higher concentrations of chemerin were observed in psoriatic patients with elevated low-density lipoptotein (LDL) cholesterol levels in comparison with patients with normal LDL values ( = 0.032). Chemerin concentrations were also significantly higher in patients with both psoriasis and elevated glucose levels compared to patients with normal blood glucose values ( = 0.043).
The results obtained suggest a possible role of chemerin as an adipokine linking psoriasis with metabolic syndrome.
近期数据表明银屑病是一种伴有多种合并症的全身性疾病，尤其是代谢综合征和心血管疾病。脂肪组织细胞分泌的脂肪因子chemerin可能是银屑病与其合并症之间的重要联系。
评估银屑病患者和健康对照组血清中chemerin的浓度，并评估脂肪因子浓度与选定的银屑病严重程度指数和代谢综合征组分之间的可能相关性。
102例确诊银屑病患者和40名健康志愿者纳入本研究。测定所有受试者血清chemerin浓度以及选定的代谢综合征组分，包括血脂和血糖水平。使用银屑病面积和严重程度指数（PASI）和体表面积（BSA）指数评估银屑病严重程度。
与对照组相比，银屑病患者组chemerin浓度更高（<0.05）。发现chemerin浓度与C反应蛋白浓度（=0.001）、体重指数（=0.031）和甘油三酯浓度（=0.043）呈正相关。还注意到与高密度脂蛋白胆固醇浓度呈负相关（=0.015）。与低密度脂蛋白（LDL）胆固醇水平正常的患者相比，LDL胆固醇水平升高的银屑病患者中chemerin浓度显著更高（=0.032）。与血糖值正常的患者相比，银屑病且血糖水平升高的患者中chemerin浓度也显著更高（=0.043）。
所得结果表明chemerin作为一种将银屑病与代谢综合征联系起来的脂肪因子可能发挥的作用。
